Ponatinib (AP24534), a multi-targeted kinase inhibitor of BCR-Abl, PDGFRα, VEGFR2, FGFR1, and Src [168] but also RET, KIT, and FLT1, is assayed as a monotherapy in recurrent GBM refractory to bevacizumab (NCT02478164). The gene discussed is FGFR1; the disease is glioblastoma.